Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$8.01 ▼ -0.52
(-6.10%)
MKT CAP: $85.6M • VOL: 30.0K
52W L $4 52W H $19
ROARABLE / RQD
D+ • 54/100
PIOTROSKI
3 / 9
ATRA // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $120.8M | $128.9M | $8.6M |
| YoY Revenue Growth % | -6.3% | +1404.0% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $35.9M | -$83.4M | -$276.0M |
| Operating Margin % | 29.7% | -64.7% | -80.0% |
| Net Income (GAAP) | $32.7M | -$85.4M | -$276.1M |
| EBITDA (Normalized) | $35.9M | -$83.2M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$50.9M | -$68.7M | -$193.0M |
| Capital Expenditures (CapEx) | $0 | $246.0K | — |
| Free Cash Flow (FCF) | -$50.9M | -$69.0M | -$193.0M |
| FCF Margin % | -42.2% | -53.5% | -80.0% |
| Return on Invested Capital (ROIC %) | 95.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $8.5M | $25.0M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | -$38.5M | -$97.3M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ATRA.